文献速递临床试验与 GCP

辅助性光磁刺激治疗静脉性及混合性腿部溃疡:NAZARÉ多中心随机对照试验方案

Adjunctive optical and magnetic stimulation for venous and mixed etiology leg ulcers: protocol for the NAZARÉ multicenter randomized controlled trial.
PubMed 文献 · Trials · 2026-06-29

NAZARÉ是一项在瑞士、法国、德国和奥地利开展的多中心、平行组、优效性IV期随机对照试验,计划纳入122例静脉性溃疡或混合性腿部溃疡成人患者。经2周标准治疗导入期确认创面面积缩小<30%后,按1:1随机分配至标准治疗+同步光磁刺激(COMS)或单纯标准治疗,主要终点为第12周创面面积缩小百分比。该试验旨在严格评估COMS作为标准治疗辅助手段的有效性。

要点

  • COMS作为标准治疗的辅助手段,其有效性尚缺乏高质量随机对照试验证据。
  • 主要终点为第12周创面面积缩小百分比,由盲法评估者采用标准化数字面积测量法评定。
  • 纳入标准包括踝肱指数>0.5且<1.30或踝动脉压>60 mmHg、溃疡面积2-50 cm2、病程>30天且<2年。

核心结论

  • 该试验将严格评估同步光磁刺激作为标准治疗辅助手段治疗静脉性及混合性腿部溃疡的有效性。

研究设计与样本

  • IV期、上市后、多中心、平行组、优效性随机对照试验,在瑞士、法国、德国和奥地利开展。
  • 计划纳入122例静脉性溃疡或混合性腿部溃疡成人患者,按1:1随机分配至标准治疗+COMS或单纯标准治疗。
  • 纳入标准:踝肱指数>0.5且<1.30或踝动脉压>60 mmHg,溃疡面积2-50 cm2,溃疡病程>30天且<2年。
  • 设置2周导入期,确认标准治疗下创面面积缩小<30%后方可随机化。

关键数值与推荐

  • 主要终点为第12周创面面积缩小百分比,由盲法评估者采用标准化数字面积测量法评定。
  • 次要终点包括完全闭合、愈合时间、疼痛、健康相关生活质量、复发和医疗资源使用。

临床怎么用

  • 若证实有效,COMS可能为慢性腿部溃疡提供一种无创、可及的治疗选择,以改善愈合结局并减轻疾病负担。

局限性

  • 缺失结局数据主要按观察到的数据分析,并可能在数据随机缺失假设下采用多重插补处理。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Venous leg ulcers (VLUs) and VLUs associated with peripheral arterial disease (PAD) are common, recurrent, and costly to manage. Adjunctive biophysical therapies may improve healing outcomes when combined with standard of care (SOC). Concurrent optical and magnetic stimulation (COMS) has shown promising mechanistic and preliminary clinical results but there is a lack of robust randomized controlled trials (RCTs). METHOD: This novel adjunct using concurrent optical and magnetic stimulation in a multicenter RCT in Europe (NAZARÉ) is a phase IV, post-market, multicenter, parallel-group, superiority randomized controlled trial conducted in Switzerland, France, Germany, and Austria. A total of 122 adults with VLU or mixed leg ulcers (ankle-brachial index > 0.5 and < 1.30 or ankle artery pressure > 60 mmHg), ulcer area 2-50 cm2, and ulcer duration > 30 days and < 2 years will be enrolled. Following a 2-week run-in to confirm < 30% area reduction under SOC, participants will be randomized 1:1 to SOC + COMS or SOC alone. The primary outcome is percentage wound area reduction (PWAR) at week 12, assessed by blinded evaluators using standardized digital planimetry. Secondary outcomes include complete closure, time-to-healing, pain, health-related quality of life, recurrence, and healthcare resource use. Missing outcome data will primarily be analyzed as observed and may be addressed using multiple imputation under the assumption of data being missing at random. DISCUSSION: This trial will rigorously assess the effectiveness of COMS as an adjunct to standard care for venous and mixed leg ulcers. By targeting chronic wounds and using a pragmatic, multicenter design, it aims to generate robust, generalizable evidence. If effective, COMS could offer a non-invasive, accessible option to enhance healing outcomes and reduce the burden of chronic leg ulcers. TRIAL REGISTRATION NUMBER: ClinicalTrials.gov NCT06528873. Registred on 26 July 2024, https://register. CLINICALTRIALS: gov/prs/app/action/SelectProtocol?selectaction=Edit&sid=S000ERKB&uid=U0003LG4 .

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Probst S, Saini C, Stefanelli A, et al. Adjunctive optical and magnetic stimulation for venous and mixed etiology leg ulcers: protocol for the NAZARÉ multicenter randomized controlled trial. Trials. 2026. PMID: 42366370. doi:10.1186/s13063-026-09859-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。